In the past decades, it has been frequently reported that BZYQT possesses a variety of immune-modulatory effects, such as stimulation of peripheral blood mononuclear cells to produce G-CSF and TNF-alpha in Hepatocellular carcinoma (HCC) patients [17], suppression of the proliferation of human hepatoma cell lines by inhibition of DNA synthesis followed by apoptosis [18], suppression of contact hypersensitivity during chronic stage [19], and reduction of IgE levels in the atopic dermatitis animal model [20]. The gene discussed is TNF; the disease is hepatocellular carcinoma.